Terminal beta-linked galactose-containing glycans

Terminal beta-linked galactose-containing glycans are essential carbohydrate motifs found on the surface of mammalian cells, primarily as components of glycoproteins and glycolipids. These structures serve as the primary recognition sites for galectins, a family of endogenous lectins that play pivotal roles in immune regulation, cell-cell adhesion, and the formation of functional molecular lattices on the cell membrane [1, 2]. Beyond their physiological roles, these glycans are frequently exploited by various pathogens, including viruses like rotavirus and bacteria like Pseudomonas aeruginosa, which utilize them as receptors for host cell attachment and entry [3]. In therapeutic contexts, these glycans are targeted through the use of glycomimetics or decoy molecules designed to inhibit galectin-mediated pathology in cancer and fibrosis or to prevent infectious diseases [4, 5]. Drugs such as Belapectin and GB0139 function by mimicking these terminal galactose structures to competitively inhibit the binding of galectins to their natural cell-surface targets. This competitive inhibition prevents the activation of downstream signaling pathways involved in chronic inflammation and fibrotic tissue remodeling. Additionally, anti-adhesion therapies targeting these glycans aim to block the initial steps of microbial colonization, providing an alternative to traditional antibiotics.

Other names

Beta-galactoside-containing glycansGalactosyl-terminated glycoconjugatesTerminal beta-galactose residuesGalectin ligandsBeta-D-galactopyranoside-containing glycans

Competitive inhibition of galectin binding; blockade of pathogen attachment; disruption of galectin-glycan lattices